tirzepatide meta analysis cardiovascular outcomes trial results july 2025 Comparative efficacy of and glucagon-like peptide-1 receptor Tirzepatide and Cancer Risk in

Critical timing for these discussions includes the initial prescribing visit, any dose escalation appointments, and whenever new medications are added to the treatment regimen

A landmark 2023 study published in JAMA found that GLP-1 agonist users experienced increased risks of gastrointestinal adverse events (with gastroparesis risk elevated compared to patients using other diabetes medications), while a 2024 case report in PMC documented the strong relationship between semaglutide use and gastroparesis symptoms that resolved only after drug discontinuation

Rats treated with IGF-1, either 24 h before ischemic AKI, immediately after or 24 h after, showed accelerated recovery of GFR and histopathological changes in damaged proximal tubular epithelia, as well as improved mortality

Why Some Fat Refuses to Leave Fat cells have receptors that either release fat or hold onto it

Pastori D, Pignatelli P, Farcomeni A, Menichelli D, Nocella C, Carnevale R, et al